Anx-131 -

For decades, the treatment of Generalized Anxiety Disorder (GAD) and post-traumatic stress disorder (PTSD) has been a pharmacological balancing act. On one side, you have benzodiazepines (Xanax, Valium)—effective but highly addictive, with tolerance and withdrawal risks. On the other, you have SSRIs (Zoloft, Prozac)—safe but slow-acting, with side effects that often make patients quit before they work.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. ANX-131 is an investigational drug that has not been approved by the FDA or other global regulatory bodies. By [Your Name/Handle] ANX-131

Watch for Phase 2 readouts in late 2027. If successful, this will be a $5 billion molecule within five years of launch. For decades, the treatment of Generalized Anxiety Disorder

ANX-131 is a . It gently reduces the overactive tonic current caused by these δ-subunits, allowing the brain’s natural phasic (on-demand) inhibition (via α1 and α2 subunits) to work properly again. By [Your Name/Handle] Watch for Phase 2 readouts

But what if there was a third path? Enter , a novel, oral, negative allosteric modulator (NAM) of the GABAA receptor.

If Phase 2 data holds up, ANX-131 could be the first oral drug for anxiety since the invention of the benzodiazepine in the 1950s.